{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:45:09Z","timestamp":1792251909627,"version":"4.4.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T00:00:00Z","timestamp":1686441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T00:00:00Z","timestamp":1686441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00415-023-11769-0","type":"journal-article","created":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T03:18:26Z","timestamp":1686453506000},"page":"4518-4522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Real-world experience with VMAT2 inhibitors in Tourette syndrome"],"prefix":"10.1007","volume":"270","author":[{"given":"Karim","family":"Makhoul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,11]]},"reference":[{"key":"11769_CR1","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1080\/14656566.2016.1258063","volume":"17","author":"J Jankovic","year":"2016","unstructured":"Jankovic J (2016) Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother 17:2461\u20132470","journal-title":"Expert Opin Pharmacother"},{"key":"11769_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107580","volume":"212","author":"J Koch","year":"2020","unstructured":"Koch J, Shi W-X, Dashtipour K (2020) VMAT2 inhibitors for the treatment of hyperkinetic movement disorders. Pharmacol Ther 212:107580","journal-title":"Pharmacol Ther"},{"key":"11769_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/14737175.2018.1403899","volume":"18","author":"H Bashir","year":"2018","unstructured":"Bashir H, Jankovic J (2018) Treatment options for chorea. Expert Rev Neurother 18:51\u201363","journal-title":"Expert Rev Neurother"},{"key":"11769_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ncl.2020.01.004","volume":"38","author":"HH Bashir","year":"2020","unstructured":"Bashir HH, Jankovic J (2020) Treatment of Tardive Dyskinesia. Neurol Clin 38:379\u2013396","journal-title":"Neurol Clin"},{"key":"11769_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-020-00914-6","author":"A Billnitzer","year":"2020","unstructured":"Billnitzer A, Jankovic J (2020) Current management of Tics and Tourette syndrome: behavioral, pharmacologic, and surgical treatments. Neurotherapeutics. https:\/\/doi.org\/10.1007\/s13311-020-00914-6","journal-title":"Neurotherapeutics"},{"key":"11769_CR6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","volume":"66","author":"SG Huntington","year":"2006","unstructured":"Huntington SG (2006) Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66:366\u2013372","journal-title":"Neurology"},{"key":"11769_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/WNF.0000000000000326","volume":"42","author":"N Niemann","year":"2019","unstructured":"Niemann N, Jankovic J (2019) Real-world experience with VMAT2 inhibitors. Clin Neuropharmacol 42:37\u201341","journal-title":"Clin Neuropharmacol"},{"key":"11769_CR8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00702-019-02105-w","volume":"127","author":"J Jankovic","year":"2020","unstructured":"Jankovic J (2020) Treatment of tics associated with Tourette syndrome. J Neural Transm 127:843\u2013850","journal-title":"J Neural Transm"},{"key":"11769_CR9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.5334\/tohm.287","volume":"6","author":"J Jankovic","year":"2016","unstructured":"Jankovic J, Jimenez-Shahed J, Budman C et al (2016) Deutetrabenazine in Tics associated with Tourette syndrome. Tremor Hyperkinetic Mov 6:422","journal-title":"Tremor Hyperkinetic Mov"},{"key":"11769_CR10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/14737175.2021.1898948","volume":"21","author":"RH Farber","year":"2021","unstructured":"Farber RH, Angelov A, Kim K et al (2021) Clinical development of valbenazine for tics associated with Tourette syndrome. Expert Rev Neurother 21:393\u2013404","journal-title":"Expert Rev Neurother"},{"issue":"10","key":"11769_CR11","doi-asserted-by":"publisher","first-page":"e2128204","DOI":"10.1001\/jamanetworkopen.2021.28204","volume":"4","author":"J Jankovic","year":"2021","unstructured":"Jankovic J, Coffey B, Claassen DO et al (2021) Safety and efficacy of flexible-dose deutetrabenazine in children and adolescents with Tourette syndrome: a randomized clinical trial. JAMA Netw Open 4(10):e2128204","journal-title":"JAMA Netw Open"},{"issue":"10","key":"11769_CR12","doi-asserted-by":"publisher","first-page":"e2129397","DOI":"10.1001\/jamanetworkopen.2021.29397","volume":"4","author":"B Coffey","year":"2021","unstructured":"Coffey B, Jankovic J, Claassen DO et al (2021) Efficacy and safety of fixed-dose deutetrabenazine in children and adolescents for tics associated with Tourette syndrome: a randomized clinical trial. JAMA Netw Open 4(10):e2129397","journal-title":"JAMA Netw Open"},{"key":"11769_CR13","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/mds.28957","volume":"37","author":"E Behling","year":"2022","unstructured":"Behling E, Farhat LC, Landeros-Weisenberger A et al (2022) Meta-analysis: efficacy and tolerability of vesicular monoamine transporter type 2 inhibitors in the treatment of Tic disorders. Mov Disord 37:684\u2013693","journal-title":"Mov Disord"},{"key":"11769_CR14","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1212\/WNL.0000000000005817","volume":"91","author":"JL Schultz","year":"2018","unstructured":"Schultz JL, Killoran A, Nopoulos PC et al (2018) Evaluating depression and suicidality in tetrabenazine users with Huntington disease. Neurology 91:e202\u2013e207","journal-title":"Neurology"},{"key":"11769_CR15","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/mds.26414","volume":"30","author":"J Jankovic","year":"2015","unstructured":"Jankovic J (2015) Therapeutic developments for tics and myoclonus. Mov Disord 30:1566\u20131573","journal-title":"Mov Disord"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11769-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11769-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11769-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T12:08:46Z","timestamp":1691755726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11769-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,11]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["11769"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11769-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,11]]},"assertion":[{"value":"19 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Makhoul declares that he has no conflicts of interest. Dr. Jankovic has received research or training grants from AbbVie Inc; CHDI Foundation; Dystonia Coalition; Medtronic Neuromodulation; Merz Pharmaceuticals; Michael J Fox Foundation for Parkinson Research; National Institutes of Health; Parkinson\u2019s Foundation; Revance Therapeutics, Inc; Teva Pharmaceutical Industries Ltd. Dr. Jankovic has served as a consultant for AbbVie Inc; Aeon BioPharma; Neurocrine; Revance Therapeutics; Teva Pharmaceutical Industries Ltd..","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}